CHICAGO, Dec. 5 /PRNewswire/ -- Each year, major corporations and their insurance companies pay out hundreds of millions of dollars in litigation settlements and jury awards for mass-tort cases by workers claiming to have been harmed by exposure to chemicals. Now a new DNA technology promises to weed out frivolous claims from the legitimate ones, saving companies and their insurers millions on such payouts and prompting reasonable settlements and resolutions.
Dr. Bruce Gillis, CEO of the genomics research group, The Cytokine Institute (TCI), is presenting a tutorial on the application of DNA lab-based evidence in workers' compensation and civil litigation at the American Bar Association's "National Program on National Trends" TIPS Staff Counsel CLE for 2008.
For the first time, litigators will tour TCI's affiliate laboratories at the University of Illinois College of Medicine at Chicago (UIC), on March 26 and 28, 2008, where they will gain hands-on experience of the new genomics- based technology, msds1(TM). The technology is already being used in some civil courts to weed out baseless lawsuits by identifying on a cellular level if an individual has suffered injury due to a specific chemical or toxic exposure.
By analyzing how 36,000 parameters of an individual's DNA are affected by specific chemicals -- including benzene, chromium, asbestos and formaldehyde -- this technology can determine with 99.9% certainty if a person was injuriously exposed to a particular toxin, thereby offering an objective methodology for providing scientifically-based evidence. Companies facing class-action and mass-tort lawsuits immediately benefit by knowing how chemicals and toxins in their workplace affect human health and the environment.
Sponsored by the ABA, and co-sponsored by the Workers' Injury Law & Advocacy Group, The College of Workers' Compensation Lawyers, The National Conference of the Administrative Law Judiciary, The American College of Occupational and Environmental Medicine (ACOEM), and The American Medical Association (AMA), the conference will be held March 26-28, 2008 at the InterContinental Hotel in Chicago, IL. It will assemble legal experts in Workers' Compensation law, products liability law, toxic tort litigation, employment law, and occupational medicine. For more information visit http://www.abanet.org/tips.
With an M.D. degree from the University of Illinois College of Medicine, a M.P.H. degree from the Harvard University School of Public Health, and medical residencies in Occupational Medicine and Medical Toxicology and in Internal Medicine, Dr. Bruce Gillis brings over 30 years of medical expertise to his position as founder and CEO of The Cytokine Institute.
The Cytokine Institute provides a variety of consulting services in the area of litigation support, risk management, human resources, medical toxicology and healthcare. The organization developed DNA-based technologies, which provide vital information that is germane to Material Safety Data Sheets, the recently enacted REACH protocol and numerous other international, and United States rules and regulations concerning potentially harmful substances.
|SOURCE The Cytokine Institute|
Copyright©2007 PR Newswire.
All rights reserved